Companies · Other Health Care
WINSTON-SALEM · Other Health Care
Diligence memoA one-page analyst read on Javara Inc. — recommendation, valuation, rhythm, risks.→Javara Inc. looks under-valued against its niche peers and is active on financing cadence.
Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the health care sector profile.
Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.
No named principal in this company's public records yet — see all operators below.
Explore how these operators interlock with other companies in the operator network.
Javara Inc. is one of 5376 Other Health Care companies tracked from WINSTON-SALEM. By capital raised it ranks among the largest (ahead of 93% of sector peers), and mid-pack by modeled valuation est..
Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.
As reported in public records reported — not modeled.
Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.
The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.
Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 75%.
Round size and date are reported; the stage label is inferred from round size (latest is Series B — a $15M–$40M round). Valuation is modeled from stage benchmarks scaled by the health care sector profile. Directional, not a quoted figure.
Benchmarked against 5376 companies in Other Health Care. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.
Raised more than 93% of sector peers (real $). Modeled value above 60% of peers (estimate).
A tighter cohort than the sector chart above — only companies at the same stage (Series B) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #37 of 48.
| Company | Stage | Raised · real | Value · est | vs peer med. |
|---|---|---|---|---|
| Imagine Pediatrics Holdings LLC | Series B | $37.6M | $201.0M | 2.18× |
| Porter Cares, Inc. | Series B | $48.5M | $183.7M | 2.00× |
| True Medicine Inc. | Series B | $42.7M | $175.7M | 1.91× |
| CranioVation, Inc. | Series B | $56.7M | $174.9M | 1.90× |
| Seriously Clean LTD. | Series B | $32.5M | $166.2M | 1.81× |
| Reprieve Cardiovascular, Inc. | Series B | $82.4M | $152.9M | 1.66× |
| CODAN US Holding Corp | Series B | $27.8M | $144.5M | 1.57× |
| CODAN US Corp | Series B | $27.7M | $144.1M | 1.57× |
| Conceivable Life Sciences Inc. | Series B | $63.5M | $142.7M | 1.55× |
| KeyCare, Inc. | Series B | $54.4M | $142.6M | 1.55× |
| Particle Dynamics Holdings, Inc. | Series B | $30.9M | $140.5M | 1.53× |
| EvolvedMD, Inc. | Series B | $49.0M | $139.0M | 1.51× |
| Javara Inc. this company | Series B | $59.7M | $33.1M | 0.36× |
Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.
| Stage | Amount · real | Announced | Post-money · est | Value · est | Conf. |
|---|---|---|---|---|---|
| Seed | $3.8M | 2019-08-08 | $18.9M | $93.6M | 90% |
| Series A | $4.6M | 2020-08-10 | $20.9M | $89.2M | 90% |
| Series A | $5.3M | 2021-08-23 | $24.0M | $70.7M | 90% |
| Series B | $30.0M | 2022-04-01 | $166.7M | $389.6M | 90% |
| Series B | $9.4M | 2023-11-01 | $52.4M | $75.5M | 90% |
| Series B | $6.6M | 2025-05-13 | $36.7M | $33.1M | 90% |
Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.
Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.
Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.
| Person | Role | Also runs | Tied since |
|---|---|---|---|
| Todd Johnson | — | 26 other | 2025-05 |
| JEFFREY KASHER | — | 2 other | 2019-08 |
| JOSEF H. VON RICKENBACH | — | 2 other | 2023-11 |
| THOMAS PIKE | — | 2 other | 2020-08 |
| ANDREW DOMESCIK | — | 1 other | 2019-08 |
| BRETT ZBAR | — | 1 other | 2022-04 |
| Josef Von Rickenbach | — | 1 other | 2025-05 |
| BRETT H. ZBAR | — | — | 2023-11 |
| CHARLES HAUSER | — | — | 2019-08 |
| CHARLES W (TODD) JOHNSON | — | — | 2021-08 |
| ERIKA H. TAUREL | — | — | 2023-11 |
| ERIKA TAUREL | — | — | 2025-05 |
| GERALD ROACH | — | — | 2019-08 |
| JENNIFER BYRNE | — | — | 2019-08 |
| JOHN VANN | — | — | 2019-08 |
| JOSEPH VON RICKENBACH | — | — | 2022-04 |
| LINDA H. MCCARTY | — | — | 2023-11 |
| LINDA MCCARTY | — | — | 2020-08 |
| THOMAS H. PIKE | — | — | 2023-11 |
Javara Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.
Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.
| Company | Sector | Stage | Raised · real | Value · est | Why similar |
|---|---|---|---|---|---|
| Project Constellation Holdings, Inc. | Other Health Care | Series B | $44.8M | $8.8M | network1 shared operator · same sector · same stage |
| Lightship Inc. | Other Health Care | Series B | $86.2M | $122.4M | network1 shared operator · same sector · same stage |
| Summus Global, Inc. | Other Health Care | Series B | $59.3M | $35.1M | same sector · same stage |
| Channel Medsystems, Inc. | Other Health Care | Series B | $54.7M | $35.8M | same sector · same stage |
| Spinal Kinetics Inc | Other Health Care | Series B | $53.7M | $28.4M | same sector · same stage |
| Impel Neuropharma Inc | Other Health Care | Series B | $51.1M | $34.4M | same sector · same stage |
| Palmaz Scientific Inc | Other Health Care | Series B | $75.0M | $29.1M | same sector · same stage |
| Klowen Braces, Inc. | Other Health Care | Series B | $44.0M | $31.9M | same sector · same stage |
Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.
| Company | Sector | Stage | Value · est | Match |
|---|---|---|---|---|
| Mitra RxDx, Inc. | Other Health Care | Series C | $1.0B | 85% |
| Iora Health, Inc. | Healthtech | Series D+ | $3.3B | 85% |
| Elira, Inc. | Other Health Care | Seed | $21.5M | 84% |
| Cura Financial Inc. | Other Health Care | Series A | $56.1M | 84% |
| Protegera, Inc. | Other Health Care | Seed | $5.5M | 84% |
| GenrAb, Inc. | Other Health Care | Series A | $38.0M | 83% |
| Theravida, Inc. | Other Health Care | Series A | $1.6M | 83% |
| J&J Solutions Inc | Other Health Care | Series A | $5.0M | 83% |
See where Javara Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.
If you work at Javara Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.
Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.